In a post-deal discussion, Incyte CEO Bill Meury said the company’s $2 billion Vega acquisition is designed to help build a “post-Jakafi future,” following his C-suite experience across multiple multibillion-dollar biopharma exits. Meury positioned Vega’s late-stage von Willebrand disease program as an important growth driver in hematology. The acquisition adds VGA039, an investigational Phase III monoclonal antibody designed for subcutaneous, once-monthly prophylaxis, intended to reduce the infusion burden of current regimens. Meury’s comments tied the rationale to the timing of Jakafi’s patent cliff. Meury also framed the transaction as one that fits Incyte’s business-development strategy: a first-in-class Phase III asset with a manageable development path and potential to deliver meaningful patient convenience. The interview underscores how senior leadership is actively shaping narrative around pipeline continuity as the company prepares for patent-driven portfolio transitions.